Last reviewed · How we verify
GRIFULVIN V (GRISEOFULVIN, MICROCRYSTALLINE)
GRIFULVIN V (generic name: GRISEOFULVIN, MICROCRYSTALLINE) is a drug developed by JOHNSON AND JOHNSON. It is currently FDA-approved for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis.
Griseofulvin is an antifungal agent used to treat conditions such as Tinea Capitis. It is available in a 125 mg/5 mL suspension form, which is administered as a single dose.
At a glance
| Generic name | GRISEOFULVIN, MICROCRYSTALLINE |
|---|---|
| Sponsor | JOHNSON AND JOHNSON |
| Target | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Onychomycosis due to dermatophyte
- Tinea barbae
- Tinea capitis
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
Key clinical trials
- A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin (Phase 1)
- A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal (Phase 1)
- Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (Phase 3)
- Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (Phase 3)
- An Open Label, Randomized, Balanced, Three Treatment, Three Period, Three Sequence, Single Dose, Crossover Study to Evaluate the Bioequivalence of Test Griseofulvin Tablets, 500 mg Versus Reference Gr (Phase 1)
- A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal (Phase 1)
- A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capi (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRIFULVIN V CI brief — competitive landscape report
- GRIFULVIN V updates RSS · CI watch RSS
- JOHNSON AND JOHNSON portfolio CI
Frequently asked questions about GRIFULVIN V
What is GRIFULVIN V?
What is GRIFULVIN V used for?
Who makes GRIFULVIN V?
What is the generic name of GRIFULVIN V?
What development phase is GRIFULVIN V in?
What does GRIFULVIN V target?
Related
- Target: All drugs targeting Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
- Manufacturer: JOHNSON AND JOHNSON — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Onychomycosis due to dermatophyte
- Indication: Drugs for Tinea barbae
- Indication: Drugs for Tinea capitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing